Showing results (801-810 of 5,983) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|January 24, 2007
Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomibJiabin An, Matthew B Rettig
Molecular Cancer Therapeutics|January 24, 2007
Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, AtiprimodSweeta R Choudhari, Muhammad A Khan, Genesis Harris, et al.
Molecular Cancer Therapeutics|January 24, 2007
The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cellsWendy L Allen, Estelle G McLean, John Boyer, et al.
Molecular Cancer Therapeutics|January 24, 2007
Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpointShi-Ken Sha, Takuji Sato, Hidetaka Kobayashi, et al.
Molecular Cancer Therapeutics|January 24, 2007
Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinomaTamantha K Stutchbury, Fares Al-Ejeh, Gillian E Stillfried, et al.
Molecular Cancer Therapeutics|January 24, 2007
Novel cell death pathways induced by N-(4-hydroxyphenyl)retinamide: therapeutic implicationsRoberta Venè, Giuseppe Arena, Alessandro Poggi, et al.
Molecular Cancer Therapeutics|January 24, 2007
The role of autophagy in the death of L1210 leukemia cells initiated by the new antitumor agents, XK469 and SH80David Kessel, John J Reiners, Stuart T Hazeldine, et al.
Molecular Cancer Therapeutics|November 24, 2006
In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trialsWanda DePinto, Xin-Jie Chu, Xuefeng Yin, et al.
Molecular Cancer Therapeutics|November 24, 2006
Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugsEmilie Roudier, Oras Mistafa, Ulla Stenius
Molecular Cancer Therapeutics|November 24, 2006
Therapeutic intervention of experimental breast cancer bone metastasis by indole-3-carbinol in SCID-human mouse modelK M Wahidur Rahman, Fazlul H Sarkar, Sanjeev Banerjee, et al.
Pageof 599